Company Overview
Ncardia is a leading provider of iPSC-derived cardiomyocytes and cardiac cell models for drug safety assessment, disease modeling, and cell therapy applications. The company specializes in producing high-quality, functionally mature human iPSC-derived cardiomyocytes that enable pharmaceutical companies to perform cardiac safety screening with human-relevant models, reducing reliance on animal testing and improving predictive accuracy for cardiotoxicity assessment.
Key Capabilities
iPSC-Derived Cardiomyocytes
High-purity, functionally mature human cardiomyocytes for cardiac safety testing, electrophysiology studies, and contractility assays with standardized quality.
Cardiac Disease Models
Patient-derived and gene-edited iPSC cardiac disease models for hypertrophic cardiomyopathy, long QT syndrome, and other cardiac conditions.
Cell Therapy Development
GMP-compatible iPSC manufacturing and differentiation services for cardiac cell therapy programs, supporting preclinical and clinical development.